Nitinol Medical Technologies' CardioSEAL
This article was originally published in The Gray Sheet
Executive Summary
Transcatheter Occlusion of Patent Foramen Ovale in Stroke Registry, announced July 27, will allow physicians worldwide to pool data on PFO closure and to support the use of the minimally invasive septal occulsion system. Nitinol is beginning a 15-center PFO trial of CardioSEAL in the U.S. and Canada